South Korea · Delayed Price · Currency is KRW Curexo Statistics
Total Valuation
Curexo has a market cap or net worth of KRW 371.75 billion. The enterprise value is 346.54 billion.
| Market Cap | 371.75B |
| Enterprise Value | 346.54B |
Important Dates
The next estimated earnings date is Wednesday, August 26, 2026.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Curexo has 41.26 million shares outstanding. The number of shares has increased by 2.01% in one year.
| Current Share Class | 41.26M |
| Shares Outstanding | 41.26M |
| Shares Change (YoY) | +2.01% |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 6.53% |
| Float | 28.54M |
Valuation Ratios
The trailing PE ratio is 68.21.
| PE Ratio | 68.21 |
| Forward PE | n/a |
| PS Ratio | 4.78 |
| PB Ratio | 3.69 |
| P/TBV Ratio | 3.71 |
| P/FCF Ratio | 4,472.53 |
| P/OCF Ratio | 489.56 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 57.48, with an EV/FCF ratio of 4,169.21.
| EV / Earnings | 62.87 |
| EV / Sales | 4.46 |
| EV / EBITDA | 57.48 |
| EV / EBIT | 106.70 |
| EV / FCF | 4,169.21 |
Financial Position
The company has a current ratio of 10.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.09 |
| Quick Ratio | 5.87 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 15.04 |
| Interest Coverage | 40.86 |
Financial Efficiency
Return on equity (ROE) is 5.67% and return on invested capital (ROIC) is 4.16%.
| Return on Equity (ROE) | 5.67% |
| Return on Assets (ROA) | 1.89% |
| Return on Invested Capital (ROIC) | 4.16% |
| Return on Capital Employed (ROCE) | 3.19% |
| Weighted Average Cost of Capital (WACC) | 10.21% |
| Revenue Per Employee | 740.39M |
| Profits Per Employee | 52.49M |
| Employee Count | 105 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Curexo has paid 121.28 million in taxes.
| Income Tax | 121.28M |
| Effective Tax Rate | 2.15% |
Stock Price Statistics
The stock price has increased by +11.10% in the last 52 weeks. The beta is 1.09, so Curexo's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +11.10% |
| 50-Day Moving Average | 8,956.80 |
| 200-Day Moving Average | 13,016.95 |
| Relative Strength Index (RSI) | 51.01 |
| Average Volume (20 Days) | 281,772 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Curexo had revenue of KRW 77.74 billion and earned 5.51 billion in profits. Earnings per share was 132.08.
| Revenue | 77.74B |
| Gross Profit | 26.44B |
| Operating Income | 3.25B |
| Pretax Income | 5.63B |
| Net Income | 5.51B |
| EBITDA | 6.03B |
| EBIT | 3.25B |
| Earnings Per Share (EPS) | 132.08 |
Balance Sheet
The company has 26.46 billion in cash and 1.25 billion in debt, with a net cash position of 25.21 billion or 611.04 per share.
| Cash & Cash Equivalents | 26.46B |
| Total Debt | 1.25B |
| Net Cash | 25.21B |
| Net Cash Per Share | 611.04 |
| Equity (Book Value) | 100.88B |
| Book Value Per Share | 2,435.80 |
| Working Capital | 87.48B |
Cash Flow
In the last 12 months, operating cash flow was 759.36 million and capital expenditures -676.24 million, giving a free cash flow of 83.12 million.
| Operating Cash Flow | 759.36M |
| Capital Expenditures | -676.24M |
| Depreciation & Amortization | 2.78B |
| Net Borrowing | -192.06M |
| Free Cash Flow | 83.12M |
| FCF Per Share | 2.01 |
Margins
Gross margin is 34.02%, with operating and profit margins of 4.18% and 7.09%.
| Gross Margin | 34.02% |
| Operating Margin | 4.18% |
| Pretax Margin | 7.25% |
| Profit Margin | 7.09% |
| EBITDA Margin | 7.76% |
| EBIT Margin | 4.18% |
| FCF Margin | 0.11% |
Dividends & Yields
Curexo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.01% |
| Shareholder Yield | -2.01% |
| Earnings Yield | 1.48% |
| FCF Yield | 0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 5, 2006. It was a forward split with a ratio of 2.
| Last Split Date | Apr 5, 2006 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Curexo has an Altman Z-Score of 28.78 and a Piotroski F-Score of 4.
| Altman Z-Score | 28.78 |
| Piotroski F-Score | 4 |